Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of the effect on heart rate variability of a beta(2)-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods
Autore:
Hanratty, CG; Silke, B; Riddell, JG;
Indirizzi:
Queens Univ Belfast, Ctr Med Biol, Whitla Div Med, Belfast BT9 7BL, Antrim, Queens Univ Belfast Belfast Antrim North Ireland BT9 7BL BT9 7BL, Antrim,
Titolo Testata:
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
fascicolo: 2, volume: 47, anno: 1999,
pagine: 157 - 166
SICI:
0306-5251(199902)47:2<157:EOTEOH>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; TIME-DOMAIN MEASURES; R-R INTERVALS; PERIOD VARIABILITY; INHALED SALBUTAMOL; FREQUENCY DOMAINS; PROGNOSTIC VALUE; METOPROLOL; BLOCKADE; SELECTIVITY;
Keywords:
heart rate variability; scatterplot; non-linear; beta-adrenoceptor; partial agonist;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Silke, B Queensrnniv Belfast, Ctr Med Biol, Whitla Div Med, Whitla Med Bldg,97 Lisbu Queens Univ Belfast Whitla Med Bldg,97 Lisburn Rd Belfast AntrimNorth Ireland BT9 7BL
Citazione:
C.G. Hanratty et al., "Evaluation of the effect on heart rate variability of a beta(2)-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods", BR J CL PH, 47(2), 1999, pp. 157-166

Abstract

Aims To examine the impact on heart rate variability (HRV), of agonism or antagonism at the cardiac beta(2)-adrenoceptor in healthy volunteers, usingstandard time-domain summary statistics and non-linear methods (scatterplot and quadrant analysis). Methods Under double-blind and randomised conditions (Latin square design), 17 normal volunteers received placebo, salbutamol (beta(2)-adrenoceptor partial agonist), ICI 118,551 (specific beta(2)-adrenoceptor antagonist), orsalbutamol plus ICI 118,551. Single oral doses of medication (at weekly intervals) were administered at 22.30 h, with HRV assessed from the sleeping heart rates. Results Salbutamol reduced the long-term (SDNN: 135 ms [120, 156], SDANN: 107 ms [89, 124]) time-domain indicators of HRV compared with placebo (SDNN: 39 [24, 55], SDANN 42 [29, 56], {mean difference [95% confidence intervals of difference]}). Alone, ICI 118,551 did not effect HRV, but in combination blocked the actions of salbutamol. Scatterplot length (944 ms [869, 1019]) and area (222(star)10(3) ms(2) [191, 253]) were reduced by salbutamol compared with placebo; (length difference (164 [98, 230]) and area difference59 [36, 83]). Scatterplot width (dispersion) was lower at both low (width RR-1 25% salbutamol 277 ms [261, 293]: salbutamol minus placebo 14 ms [0, 28]) and high (width 75% salbutamol 417 [391, 443]: salbutamol minus placebo41 [20, 62]) heart rates. ICI 118,551 alone did not alter scatterplot parameters but in combination blocked the effect of salbutamol. Cardiac acceleration episodes (i.e. consecutive Delta RR and Delta RRn+1 shorten) were increased following salbutamol 7288 [6089, 8486] compared with placebo -1890 [-2600, -1179]; the beat-to beat difference (Delta RRn+1) was reduced after salbutamol compared with the other treatments. ICI 118,551 did not effect acceleration episodes but reduced the effect of salbutamol when used in combination. Conclusions Agonism at the cardiac beta(2)-adrenoceptor in healthy volunteers with salbutamol altered autonomic balance towards sympathetic dominance; this re-balancing was blocked by ICI 118,551 given in combination with salbutamol. However antagonism at the beta(2)-adrenoceptor with ICI 118,551 alone did not significantly alter the HRV. The beta(2)-adrenoceptor modulates HRV in healthy volunteers; the implications of agonism and antagonism at the beta(2)-adrenoceptor in cardiovascular disease states warrants further investigation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 04:24:22